Interest of a Dose Decrease for Radiotherapy Associated With Chemotherapy for Treatment of Standard Risk Adult Medulloblastomas

Launched by CENTRAL HOSPITAL, NANCY, FRANCE · May 16, 2013

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Pathologic diagnosis of medulloblastoma expect large cells type
• • Patients between 18 and 70 years
• • Résidual tumor les than 1.5 square centimeter (greater diameter)
• • No sus tentorial or spinal location
• • Absence of tumoral cells in the cerebrospinal fluid taken before, during or 14 days after surgery
• • Absence of MYC amplification
• • AID, B and C hepatitis positive serologies
• • Negative βHCG dosage and effective contraception for potentially pregnant women
• • Writed consent obtain
• Exclusion Criteria:
• • Age \< 18 or \> 70 years
• • Previous diagnosis of medulloblastoma
• • Previous treatment with chemotherapy
• • Previous cranial or spinal radiation therapy
• • Carboplatinum or etoposide contraindication
• • Previous cancer in the five years before the inclusion except basocellular carcinoma of the skin and in situ cancer of the uterine cervix
• • Severe renal renal insufficiency with a creatinine clearance \< 60 ml/min
• • Liver insufficiency with a contraindication of carboplatinum or etoposide based chemotherapy or elevated transaminases \> 3N.
• • Insufficient haematopoetic reserve (thrombocytes \< 100 000/mm3 ou neutrophil polynuclear \< 1500/mm3)
• • Previous organ transplantation or immunosuppression
• • Pregnant women or women without contraception
• • Incapacity of respecting the recommanded follow up
• • Participation in another therapeutic clinical trial
• • Patient under custody
• • Not social security regime membership